CSPHF (CStone Pharmaceuticals) Marketable Securities: $23.43 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSPHF CStone Pharmaceuticals CSPHF
47 GF Score
Price $0.71
GF Value $0.15
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Marketable Securities?

CStone Pharmaceuticals CSPHF +19.43% 47 Marketable Securities is $23.43 Mil as of Dec. 2025. GuruFocus rates CSPHF with a GF Score™ of 47/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. CStone Pharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2025 was $23.43 Mil.

CStone Pharmaceuticals's annual Marketable Securities increased from Dec. 2023 ($4.20 Mil) to Dec. 2024 ($39.15 Mil) but then declined from Dec. 2024 ($39.15 Mil) to Dec. 2025 ($23.43 Mil).

CStone Pharmaceuticals  (OTCPK:CSPHF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

CStone Pharmaceuticals Marketable Securities Related Terms

CStone Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for CStone Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CStone Pharmaceuticals Marketable Securities Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 154.43 69.34 4.20 39.15 23.43

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.20 18.61 39.15 27.16 23.43
CSPHF
47GF Score
CStone Pharmaceuticals CSPHF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CStone Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $23.43 Mil mean?
CStone Pharmaceuticals (CSPHF) has a Marketable Securities of $23.43 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CStone Pharmaceuticals and its competitors.
Is CStone Pharmaceuticals' Marketable Securities too high?
CStone Pharmaceuticals' current Marketable Securities is $23.43 Mil. Overall, CStone Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CStone Pharmaceuticals' Marketable Securities compare to VRTX and REGN?
CStone Pharmaceuticals' Marketable Securities of $23.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on CStone Pharmaceuticals and its competitors. CStone Pharmaceuticals's current Marketable Securities is $23.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CStone Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CStone Pharmaceuticals (CSPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.71 — trading 373.3% above its estimated fair value. The current Marketable Securities is $23.43 Mil. CStone Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For CStone Pharmaceuticals (CSPHF), the current Marketable Securities is $23.43 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CStone Pharmaceuticals (CSPHF) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of $0.71 is trading 373.3% above its estimated GF Value™ of $0.15. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CSPHF:

  • Marketable Securities: $23.43 Mil
  • GF Value™: $0.15 vs. price of $0.71 (373.3% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the CSPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CStone Pharmaceuticals Business Description

Other Exchanges 02616:Hong KongPH4:Germany
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
47GF Score

Get the complete analysis for CSPHF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$0.15
GF Value